Lei Fan, Zhong-Hua Wang, Lin-Xiaoxi Ma, Song-Yang Wu, Jiong Wu, Ke-Da Yu, Xin-Yi Sui, Ying Xu, Xi-Yu Liu, Li Chen, Wen-Juan Zhang, Xi Jin, Qin Xiao, Ruo-Hong Shui, Yi Xiao, Han Wang, Yun-Song Yang, Xiao-Yan Huang, A-Yong Cao, Jun-Jie Li, Gen-Hong Di, Guang-Yu Liu, Wen-Tao Yang, Xin Hu, Yan Xia, Qian-Nan Liang, Yi-Zhou Jiang, Zhi-Ming Shao
BACKGROUND: Triple-negative breast cancers display heterogeneity in molecular drivers and immune traits. We previously classified triple-negative breast cancers into four subtypes: luminal androgen receptor (LAR), immunomodulatory, basal-like immune-suppressed (BLIS), and mesenchymal-like (MES). Here, we aimed to evaluate the efficacy and safety of subtyping-based therapy in the first-line treatment of triple-negative breast cancer. METHODS: FUTURE-SUPER is an ongoing, open-label, randomised, controlled phase 2 trial being conducted at Fudan University Shanghai Cancer Center (FUSCC), Shanghai, China...
February 2024: Lancet Oncology